# RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

> **NCT00935961** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- HEAD & NECK Cancer

## Interventions

- **DRUG:** RAD001 + docetaxel + cisplatin

## Key facts

- **NCT ID:** NCT00935961
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00935961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00935961, "RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00935961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*